Ducharme Erin, Weinberg Jeffrey M
St. Luke's-Roosevelt Hospital Center, Department of Dermatology, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA.
Expert Opin Biol Ther. 2008 Apr;8(4):491-502. doi: 10.1517/14712598.8.4.491.
In some patients with psoriasis the inflammatory process fueling skin lesions also afflicts their joints in a condition called psoriatic arthritis. TNF-alpha has been shown to play a central role in the pathogenesis of both cutaneous and joint disease. Etanercept is a soluble fusion protein that binds TNF-alpha, rendering the molecule inactive and making etanercept an effective, targeted therapeutic option for many TNF-mediated inflammatory diseases.
To review the key clinical trials which evaluated efficacy of etanercept for the treatment of psoriasis and psoriatic arthritis, discuss various off-label uses for this therapeutic agent and describe the adverse events associated with its use.
A search of Medline for relevant articles on etanercept and psoriasis.
RESULTS/CONCLUSION: Etanercept has demonstrated efficacy in the treatment of skin and joint manifestations of psoriatic disease, thus gaining FDA approval for use in both. A growing number of off-label dermatological uses for etanercept have been proposed, with variable success reported in individual cases or small series. Since its introduction little over a decade ago, etanercept has maintained a favorable safety profile.
在一些银屑病患者中，引发皮肤病变的炎症过程也会累及他们的关节，这种病症称为银屑病关节炎。肿瘤坏死因子-α（TNF-α）已被证明在皮肤和关节疾病的发病机制中起核心作用。依那西普是一种可溶性融合蛋白，可与TNF-α结合，使该分子失活，从而使依那西普成为许多TNF介导的炎症性疾病的有效靶向治疗选择。
回顾评估依那西普治疗银屑病和银屑病关节炎疗效的关键临床试验，讨论该治疗药物的各种非适应证用药情况，并描述与其使用相关的不良事件。
在Medline上搜索有关依那西普和银屑病的相关文章。
结果/结论：依那西普已证明对银屑病的皮肤和关节表现具有治疗效果，因此获得了美国食品药品监督管理局（FDA）在这两方面的使用批准。依那西普越来越多的非适应证皮肤科用药情况已被提出，在个别病例或小系列研究中报告的成功率各不相同。自十多年前问世以来，依那西普一直保持着良好的安全性。
